HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Purdue Pharma L.P.

http://www.purduepharma.com/

Latest From Purdue Pharma L.P.

Chiesi Takes Long View To Build Japan Rare Disease Presence

After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances. 

Japan Rare Diseases

Talc Litigation Attorneys Allege ‘Bad Faith Filings,’ ‘Fraudulent Activities’ By J&J In Bankruptcy

Attorneys for some plaintiffs alleging harm from talc products J&J marketed ask a court to order the firm, along with a subsidiary holding company it created in 2021 to manage its talc liabilities and immediately placed in bankruptcy, to provide emails and other communications among in-house counsel and compel their testimony.

Cosmetics OTC Drugs

Supreme Court Decision Derailing Purdue Pharma Bankruptcy Could Trip J&J Talc Litigation Strategy

Supreme Court ruling on Purdue bankruptcy should “derail any attempt by J&J to return the talc litigation to the bankruptcy courts,” says class action plaintiff’s attorney. A federal court, Justice Gorsuch states, relieved Purdue owners of liability “without securing the consent of those affected or placing anything approaching their total assets on the table.”

OTC Drugs Litigation

Purdue Bankruptcy Settlement ‘Back To Square One’ After US Supreme Court Rejection

In a 5-4 decision, the high court says a Chapter 11 bankruptcy plan provision releasing the Sackler family from future liability is not allowed, a decision that could spur a bolus of personal injury trials if another reorganization plan settling thousands of claims cannot be reached.

Advertising, Marketing & Sales Legal Issues
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Imbrium Therapeutics L.P.
    • Adlon Therapeutics L.P
    • Rhodes Pharmaceuticals LP
    • CoCensys Inc
UsernamePublicRestriction

Register